Novo Nordisk Readies for Pipeline Showcase as EU Clears Wegovy Pill and High-Dose Pen
EU green lights oral and high-dose Wegovy; CagriSema phase 3 data at ADA. Stock down 45% from high…
Novo Nordisk Turns a Corner: EU Panel Backs Both Oral and High-Dose Wegovy as US Sales Surprise
European Medicines Agency backs two Wegovy formulations; oral tablet becomes first GLP-1 pill for weight loss in EU.…
Novo Nordisk’s High-Dose Shot and Amazon Push Provide Lift, Yet Stock Sags on Generics and FDA Rev
Despite strong weight-loss data and an Amazon Pharmacy deal, Novo Nordisk shares slump on patent cliff fears, FDA…
Novo Nordisk Scraps Rare-Disease Plant and Unleashes High-Dose Data to Fortify GLP-1 Empire
Novo Nordisk shifts focus to weight-loss drugs, converting a rare-disease factory into GLP-1 warehousing. Q1 earnings beat estimates…
High-Dose Wegovy Fat-Loss Data and Hemophilia Drug Near Approva
Novo Nordisk reveals STEP-UP trial data for high-dose Wegovy showing 21% weight loss with muscle preservation, alongside hemophilia…
Novo Nordisk Sharpens Obesity Arsenal With High-Dose Wegovy Data and a Strategic Portfolio Pruning
Novo Nordisk divests Parkinson’s therapy to focus on obesity, unveils strong high-dose Wegovy data, and raises 2026 guidance…
Novo Nordisk’s AI Bet and High-Dose Launch Face a Revenue Reality Check
Novo Nordisk shares surge on OpenAI partnership and buybacks, but Wall Street is cautious due to sales mix,…